Palomar Medical Technologies and Reliant Technologies Announce Launch of a Fractional Technology Licensing Program
12 11월 2008 - 8:00AM
PR Newswire (US)
Program to Offer Licenses to Fundamental Fractional Patent Families
BURLINGTON, Mass., Nov. 11 /PRNewswire-FirstCall/ -- Palomar
Medical Technologies, Inc. (NASDAQ:PMTI) and Reliant Technologies,
Inc., today announced the formation of a Fractional Technology Open
Patent Program ("FTOPP") to offer licenses in the professional
field to key intellectual property in the fractional space. The
FTOPP contains six fundamental fractional patent families including
issued patents and pending patent applications owned or controlled
by Palomar, Reliant and Massachusetts General Hospital ("MGH"). In
addition to this program Palomar and Reliant have entered into
certain cross-licenses between the two companies. Fractional
light-based treatments deliver laser or high-powered light energy
in a pattern that leaves untreated areas of skin between the
treated areas of skin. The healthy, untreated areas promote faster
healing of the treated areas and stimulate increased clinical
response as compared to standard full surface treatments. Clinical
studies show fractional treatments can increase both efficacy and
safety. Fractional treatments have quickly become one of the most
widely accepted and sought after new dermatology treatments. In
response, many companies have launched new fractional products to
meet the large market demand. As pioneers of fractional technology,
Palomar, Reliant and MGH are the owners of the fundamental
intellectual property in this area. In order to encourage further
development of fractional products while also seeking compensation
for their early, ground breaking work, Palomar, Reliant and MGH
have created the FTOPP to provide others in the industry the
opportunity to license the necessary intellectual property. "We are
excited to be a part of this program," said Dr. R. Rox Anderson,
Director of the Wellman Center for Photomedicine, Massachusetts
General Hospital. "Fractional treatment is a broad technology that
enhances safety and efficacy over that of traditional light-based
aesthetic treatments. Our work has already helped many people
around the world. This program enables participants to benefit from
years of research and continue development of an important new
approach." "Palomar is recognized as a technology leader with one
of the strongest intellectual property portfolios and patent
enforcement strategies in the industry," said Joe Caruso, President
and CEO of Palomar Medical Technologies. "The FTOPP presents a
compelling collection of intellectual property assets that are
necessary to operate in the fractional space. We believe companies
exploiting fractional technology will find it in their interest to
take an FTOPP license and not risk the consequences of infringing
such a large number of patents." "Investing in innovation is key to
the success of Reliant Technologies and it is imperative that
Reliant protect the value of its inventions," said Eric Stang,
President and CEO of Reliant Technologies. "By forming this FTOPP
in conjunction with Palomar and MGH, we are making it possible for
companies to access and take advantage of fundamental intellectual
property in the fractional space." The FTOPP comprises six patent
families, including eleven issued and pending U.S. patents and
applications, along with foreign counterparts. Included in the
FTOPP from Palomar Medical Technologies are: U.S. patent number
6,997,923 and patent application number 11/235,697 (the "923"
patent family -- jointly owned with and licensed by Palomar from
MGH); and U.S. patent number 6,723,090 and patent application
number 11/408,272 (the "Fiber Laser" patent family). Included in
the FTOPP from Reliant are: U.S. patent numbers 6,632,219 and
6,059,820 and patent application number 11/250,139 (the
"Tankovich-Baranov" patent family, named for early inventors in the
fractional space Dr. Nikolai Tankovich and Dr. Eugene Baranov) ;
U.S. patent application number 10/542,390 (the "1678" patent family
licensed by Reliant from MGH); and U.S. patent application number
10/367,582 (the "582" patent family). Also included in the FTOPP
from MGH is U.S. patent number 7,331,953 and patent application
number 11/931,232 (the"953" patent family). Recently, it was
announced that Reliant has agreed to join forces with Thermage,
Inc. (NASDAQ:THRM) in a merger expected to close in the Fourth
quarter 2008. For more information, visit http://www.fraxel.com/.
About Palomar Medical Technologies, Inc.: Palomar is a leading
researcher and developer of light-based systems for cosmetic
treatments. Palomar pioneered the optical hair removal field, when,
in 1997, it introduced the first high-powered laser hair removal
system. Since then, many of the major advances in light-based hair
removal have been based on Palomar technology. In December 2006,
Palomar became the first company to receive a 510(k)
over-the-counter (OTC) clearance from the United States Food and
Drug Administration (FDA) for a new, patented, home use,
light-based hair removal device. OTC clearance allows the product
to be marketed and sold directly to consumers without a
prescription. There are now millions of light-based cosmetic
procedures performed around the world every year in physician
offices, clinics, spas and salons. Palomar is testing many new and
exciting applications to further advance the hair removal market
and other cosmetic applications. Palomar is focused on developing
proprietary light-based technology for introduction to the mass
markets. Palomar has granted The Procter & Gamble Company a
non-exclusive License Agreement to certain patents, technology and
FDA documents related to the home-use, light-based hair removal
field for women. In addition, Palomar has an exclusive development
and license agreement with Johnson & Johnson Consumer Companies
to develop and potentially commercialize home-use, light-based
devices for reducing or reshaping body fat including cellulite,
reducing the appearance of skin aging, and reducing or preventing
acne. About Reliant Technologies: Reliant Technologies develops
clinical solutions to rejuvenate aging and environmentally damaged
skin. Reliant is dedicated to providing the most ergonomic and
effective products to the global aesthetic marketplace. The company
pioneered the development of fractional laser resurfacing that
relies on novel high-speed scanning systems and the Intelligent
Optical Tracking(R) system to produce safe and effective results
with minimal recovery time. Reliant is based in Mountain View,
Calif. The Fraxel(R) family of products, which includes the Fraxel
re:pair(TM), Fraxel re:store(TM) and Fraxel re:fine(TM) laser
systems, has quickly become the industry standard for fractional
aesthetic skin treatment. Unlike laser devices of the past, Fraxel
brand laser systems treat microscopic volumes of skin with each
unique pulse, leaving the surrounding area intact for fast healing.
Fraxel lasers have received multiple FDA clearances and have been
found safe and effective in treating many areas of the face and
body. The versatility of the product line ensures that patients can
choose the best treatment for various stages of their lives as
their skin care needs evolve. Contacts: Kayla Castle Investor
Relations Manager Palomar Medical Technologies, Inc. 781-993-2411
DATASOURCE: Palomar Medical Technologies, Inc. CONTACT: Kayla
Castle, Investor Relations Manager of Palomar Medical Technologies,
Inc., +1-781-993-2411, Web site: http://www.palmed.com/ Company
News On-Call: http://www.prnewswire.com/comp/107555.html
Copyright
Palomar Medical Technologies, Inc. (MM) (NASDAQ:PMTI)
과거 데이터 주식 차트
부터 6월(6) 2024 으로 7월(7) 2024
Palomar Medical Technologies, Inc. (MM) (NASDAQ:PMTI)
과거 데이터 주식 차트
부터 7월(7) 2023 으로 7월(7) 2024